Cargando…

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen

Detalles Bibliográficos
Autores principales:	Palmen, Breanna, Hari, Parameswaran, D’Souza, Anita, Abid, Muhammad Bilal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620554/ https://www.ncbi.nlm.nih.gov/pubmed/37051742 http://dx.doi.org/10.3324/haematol.2023.283003

Ejemplares similares

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma
por: Yoneyama, Tomoki, et al.
Publicado: (2022)

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
por: Huo, Jianxin, et al.
Publicado: (2022)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
por: D'Souza, Anita, et al.
Publicado: (2022)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Protracted Hiccups Induced by Aripiprazole and Regressed after Administration of Gabapentin
por: Carbone, Manuel Glauco, et al.
Publicado: (2021)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Anderson, John, et al.
Publicado: (2023)

The protracted maturation of human ESC-derived interneurons
por: Tyson, Jennifer A, et al.
Publicado: (2013)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

A Case of Protracted Labor
por: Bhattacharjee, Hari Mohun
Publicado: (1886)

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
por: D’Souza, Anita, et al.
Publicado: (2017)

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
por: Markouli, Mariam, et al.
Publicado: (2023)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2ds2qkiti1909kjhd196v7019a